Sally Aldous1, A Mark Richards2, Peter M George3, Louise Cullen4, William A Parsonage4, Dylan Flaws5, Christopher M Florkowski3, Richard W Troughton6, Jack W O'Sullivan4, Christopher M Reid7, Laura Bannister8, Martin Than8. 1. Department of Cardiology, Christchurch Hospital, Riccarton Avenue, Christchurch, New Zealand. Electronic address: sally.aldous@cdhb.health.nz. 2. Christchurch Hospital, Christchurch, New Zealand; University of Otago, Christchurch, New Zealand; National University Heart Centre, Singapore. 3. Canterbury Health Laboratories, Christchurch, New Zealand. 4. Royal Brisbane and Women's Hospital, Brisbane, Australia. 5. University of Technology, Brisbane, Australia. 6. Christchurch Hospital, Christchurch, New Zealand; University of Otago, Christchurch, New Zealand. 7. Monash University, Melbourne, Australia. 8. Christchurch Hospital, Christchurch, New Zealand.
Abstract
OBJECTIVES: The aim of this study is to compare a new improved point of care cardiac troponin assay (new POC-cTnI) with 1. its predecessor (old POC-cTnI) and 2. a high sensitivity assay (hs-cTnI) for the diagnosis of acute myocardial infarction (AMI) and for major adverse cardiac events (MACE) by 30 days. METHODS: This is a single centre observational study, set in Christchurch Hospital, New Zealand. Patients presenting to the emergency department with non-traumatic chest pain underwent blood sampling at 0 h and 2h post presentation for analysis with the 3 cTnI assays for the outcome of AMI and for analysis using an accelerated diagnostic protocol (ADP-normal 2h troponins, normal electrocardiograms and Thrombolysis In Myocardial Infarction (TIMI) score of 0 or ≤ 1) for 30 day MACE. RESULTS: Of 962 patients, 220 (22.9%) had AMI. Old POC-cTnI was least sensitive at 70.0% (65.4-73.9%) by 2h (p<0.001). New POC-cTnI, sensitivity 93.6% (89.9-96.2%) had similar sensitivity to hs-cTnI, sensitivity 95.0% (91.5-97.3%) (p = 0.508). There were 231 (24.0%) patients with 30 day MACE. When used as part of the ADP, all assays had 100% (98.0-100%) sensitivity using TIMI = 0. Sensitivities of new POC-cTnI ADP, 98.3% (95.4-99.4%), old POC-cTnI, 96.5% (93.2-98.4%) and hs-cTnI, 98.7% (96.0-99.7%) were similar (p = 0.063-0.375) using TIMI ≤ 1. CONCLUSIONS: A new POC-cTnI has improved sensitivity for AMI and MACE compared with its predecessor and comparable sensitivity to a high sensitivity assay. Now that sensitivities of the POC assay are improved, the new assay may be a useful alternative to central laboratory assays when rapid turn-around times are not possible.
OBJECTIVES: The aim of this study is to compare a new improved point of care cardiac troponin assay (new POC-cTnI) with 1. its predecessor (old POC-cTnI) and 2. a high sensitivity assay (hs-cTnI) for the diagnosis of acute myocardial infarction (AMI) and for major adverse cardiac events (MACE) by 30 days. METHODS: This is a single centre observational study, set in Christchurch Hospital, New Zealand. Patients presenting to the emergency department with non-traumatic chest pain underwent blood sampling at 0 h and 2h post presentation for analysis with the 3 cTnI assays for the outcome of AMI and for analysis using an accelerated diagnostic protocol (ADP-normal 2h troponins, normal electrocardiograms and Thrombolysis In Myocardial Infarction (TIMI) score of 0 or ≤ 1) for 30 day MACE. RESULTS: Of 962 patients, 220 (22.9%) had AMI. Old POC-cTnI was least sensitive at 70.0% (65.4-73.9%) by 2h (p<0.001). New POC-cTnI, sensitivity 93.6% (89.9-96.2%) had similar sensitivity to hs-cTnI, sensitivity 95.0% (91.5-97.3%) (p = 0.508). There were 231 (24.0%) patients with 30 day MACE. When used as part of the ADP, all assays had 100% (98.0-100%) sensitivity using TIMI = 0. Sensitivities of new POC-cTnIADP, 98.3% (95.4-99.4%), old POC-cTnI, 96.5% (93.2-98.4%) and hs-cTnI, 98.7% (96.0-99.7%) were similar (p = 0.063-0.375) using TIMI ≤ 1. CONCLUSIONS: A new POC-cTnI has improved sensitivity for AMI and MACE compared with its predecessor and comparable sensitivity to a high sensitivity assay. Now that sensitivities of the POC assay are improved, the new assay may be a useful alternative to central laboratory assays when rapid turn-around times are not possible.
Keywords:
Accelerated diagnostic protocol; Acute myocardial infarction; High sensitivity troponin; Major adverse cardiac events; Point of care troponin
Authors: Simon A Mahler; Jason P Stopyra; Fred S Apple; Robert F Riley; Gregory B Russell; Brian C Hiestand; James W Hoekstra; Cedric W Lefebvre; Bret A Nicks; David M Cline; Kim L Askew; David M Herrington; Gregory L Burke; Chadwick D Miller Journal: Clin Biochem Date: 2017-01-10 Impact factor: 3.281
Authors: Olga Rodenko; Susann Eriksson; Peter Tidemand-Lichtenberg; Carl Peder Troldborg; Henrik Fodgaard; Sylvana van Os; Christian Pedersen Journal: Biomed Opt Express Date: 2017-07-20 Impact factor: 3.732
Authors: Tim Norman; Joanna Young; Jo Scott Jones; Gishani Egan; John Pickering; Stephen Du Toit; Fraser Hamilton; Rory Miller; Chris Frampton; Gerard Devlin; Peter George; Martin Than Journal: BMJ Open Date: 2022-04-15 Impact factor: 3.006
Authors: L H Koper; L D S Frenk; J G Meeder; F H M van Osch; A L Bruinen; M J W Janssen; A W J van 't Hof; B M Rahel Journal: Neth Heart J Date: 2021-11-24 Impact factor: 2.854
Authors: Emanuela Angeli; Sabrina Martens; Lucio Careddu; Francesco D Petridis; Andrea G Quarti; Cristina Ciuca; Anna Balducci; Assunta Fabozzo; Luca Ragni; Andrea Donti; Gaetano D Gargiulo Journal: Interact Cardiovasc Thorac Surg Date: 2021-01-22
Authors: Michelle M A Kip; Hendrik Koffijberg; Marco J Moesker; Maarten J IJzerman; Ron Kusters Journal: BMC Cardiovasc Disord Date: 2017-08-02 Impact factor: 2.298